Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease

Phase 4

Terminated

Conditions: Peripheral Artery Disease

Interventions: Drug: Metformin 1000 mg
Drug: Placebo

Registration Number: NCT01901224

Lead Sponsor: Brigham and Women's Hospital

Brief Summary: The investigators are doing this research study to find out if taking Metformin improves walking ability in patients with peripheral arterial disease (PAD). In PAD the arteries (blood vessels) in the legs are narrowed because of the build up of plaque. The leg muscle can hurt in patients with PAD and this is usually described as a cramp or tiredness. This pain is called intermittent claudication. Metformin is an FDA approved medication for the treatment of diabetes. The investigators believe that Metformin may help your leg muscles work better.

The investigators will enroll up to 100 subjects in order to find 60 subjects with PAD at Brigham and Women's Hospital (BWH).

Detailed Description: Peripheral artery disease (PAD) is a manifestation of atherosclerosis that affects more than 7 million adults in the US. The prevalence of PAD increases with age and is estimated to be 15 20% among individuals 65 years of age and older. Patients with PAD have limited functional capacity; they walk more slowly and have less walking endurance than persons who do not have PAD, irrespective of whether they have classic symptoms of intermittent claudication or critical limb ischemia. This functional impairment adversely affects quality of life. Although flow limitation due to atherosclerotic stenosis is necessary for the development of symptoms in PAD, the lack of correlation between walking capacity and the degree of hemodynamic compromise raises the possibility that alternative mechanisms contribute to functional limitations in these patients. Putative mechanisms include inadequate skeletal muscle glucose uptake, altered skeletal muscle energetics, and impaired vasomotor tone and nutrient delivery mediated by endothelial dysfunction. Metformin, via AMPactivated protein kinase (AMPK)-dependent and independent mechanisms, can favorably affect skeletal muscle metabolic functions including glucose uptake, fatty acid oxidation, mitochondrial function, and consequently cellular energetics, and it also may have a direct salutary effect on vascular function via regulation of nitric oxide synthase. It is intriguing, therefore, to consider the possibility that metformin would improve skeletal muscle metabolic and vascular function in older patients with PAD and translate into functional benefits. Accordingly, the investigators seek to elucidate molecular mechanisms through which metformin affects skeletal muscle energetics and hypothesize that metformin will lead to advantageous metabolic, vascular, and physical functional changes in older patients with PAD.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 2

Inclusion Criteria

Age 40 years or greater
Intermittent claudication for 6 months or greater
Maximal walk time between 1-20 minutes on all ETTs
Resting ABI ≤ 0.9 in index leg at baseline
ABI falls ≥ 20% in index leg 1 minute post baseline ETT
MWT variability < 20%

Exclusion Criteria

Type 1 or Type 2 Diabetes
Limb-threatening ischemia (rest pain, ulceration, gangrene)
Peripheral vascular surgery or PCI within 6 months
MI or CABG within 6 months
Carotid endarterectomy (CEA) within 6 months
Cerebrovascular accident or TIA within 6 months
Uncontrolled hypertension (SBP > 140 mmHg, DBP >90 mmHg)
Pentoxifylline/Cilostazol added/changed within 3 months
HMG-CoA reductase inhibitor added/changed within 3 months
Exercise limitations other than claudication (heart failure, angina, COPD, arthritis, neuropathy, etc.)
Serum creatinine ≥ 1.5 mg/dL
Pregnant or plans to become pregnant
2 hour Oral Glucose Tolerance Test (OGTT) > 200 mg/dL

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Metformin 1000 mg	Metformin 1000 mg	metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
Control	Placebo	placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.

Primary Outcome Measures

Name	Time	Method
Change in PCr Recovery Time	baseline, 12 weeks	PCr recovery time, measured in seconds, is a measure of skeletal muscle metabolic function. PCr is a transport molecule and reservoir of high-energy phosphate bonds, which is important for cellular energetics. Phosphocreatine regeneration depends upon the skeletal muscle mitochondrial cells capacity for oxidative phosphorylation. We will measure PCr recovery time at baseline and after 12 weeks of treatment with metformin or placebo as an in vivo measure of mitochondrial function. Higher Pcr relative to P(i) during recovery is better and shorter recovery times are better.

Secondary Outcome Measures

Name	Time	Method
Change in Flow-mediated Dilation (FMD)	baseline, 12 weeks	Flow mediated vasodilation of the brachial artery is a measure of endothelium-dependent vasodilation. Higher flow-mediated dilation (FMD), measured as the diameter of the brachial artery in millimeters, and reported as percent change after a flow stimulus compered to basal measurement, is better, indicative of better endothelial function.